Arthur C. Santora II - Sep 7, 2022 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Signature
/s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Stock symbol
ENTX
Transactions as of
Sep 7, 2022
Transactions value $
$0
Form type
4
Date filed
9/9/2022, 04:09 PM
Previous filing
Jan 14, 2022
Next filing
Apr 25, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTX Stock Option (right to buy) Award $0 +20K $0.00 20K Sep 7, 2022 Ordinary Shares, par value NIS 0.0000769 per share 20K $2.86 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This grant of options was approved by the Board of Directors of Entera Bio Ltd. (the "Company") on March 31, 2021, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on March 31, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.